Why the study?
Does trimetazidine reduce all-cause mortality and heart failure hospitalizations in patients with ischemic cardiomyopathy?
Population
61 patients with ischemic dilated cardiomyopathy (chronic heart failure)
Comparison
Trimetazidine 20 mg tid added to conventional… vs Usual drug therapy for 4 years
Design
RCT, randomized, open-label
Follow-up
48 months
Authors
Loading...
Supports trimetazidine addition in ischemic cardiomyopathy; confirms mortality benefit in RCT.
Does trimetazidine reduce all-cause mortality and heart failure hospitalizations in patients with ischemic cardiomyopathy?
Long-term addition of trimetazidine to usual therapy significantly reduces mortality and heart failure hospitalizations in patients with ischemic cardiomyopathy.
Napoli et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: